<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35064929</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1531-8249</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>91</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Annals of neurology</Title>
          <ISOAbbreviation>Ann Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Muscle Transcriptomics Shows Overexpression of Cadherin 1 in Inclusion Body Myositis.</ArticleTitle>
        <Pagination>
          <StartPage>317</StartPage>
          <EndPage>328</EndPage>
          <MedlinePgn>317-328</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26304</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">This study aimed to elucidate the molecular features of inclusion body myositis (IBM).</AbstractText>
          <AbstractText Label="METHODS">We performed RNA sequencing analysis of muscle biopsy samples from 67 participants, consisting of 58 myositis patients with the pathological finding of CD8-positive T cells invading non-necrotic muscle fibers expressing major histocompatibility complex class I (43 IBM, 6 polymyositis, and 9 unclassifiable myositis), and 9 controls.</AbstractText>
          <AbstractText Label="RESULTS">Cluster analysis, principal component analysis, and pathway analysis showed that differentially expressed genes and pathways identified in IBM and polymyositis were mostly comparable. However, pathways related to cell adhesion molecules were upregulated in IBM as compared with polymyositis and controls (p &lt; 0.01). Notably, CDH1, which encodes the epidermal cell junction protein cadherin 1, was overexpressed in the muscles of IBM, which was validated by another RNA sequencing dataset from previous publications. Western blotting confirmed the presence of mature cadherin 1 protein in the muscles of IBM. Immunohistochemical staining confirmed the positivity for anti-cadherin 1 antibody in the muscles of IBM, whereas there was no muscle fiber positive for anti-cadherin 1 antibody in immune-mediated necrotizing myopathy, antisynthetase syndrome, and controls. The fibers stained with anti-cadherin 1 antibody did not have rimmed vacuoles or abnormal protein accumulation. Experimental skeletal muscle regeneration and differentiation systems showed that CDH1 is expressed during skeletal muscle regeneration and differentiation.</AbstractText>
          <AbstractText Label="INTERPRETATION">CDH1 was detected as a differentially expressed gene, and immunohistochemistry showed that cadherin 1 exists in the muscles of IBM, whereas it was rarely seen in those of other idiopathic inflammatory myopathies. Cadherin 1 upregulation in muscle could provide a valuable clue to the pathological mechanisms of IBM. ANN NEUROL 2022;91:317-328.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ikenaga</LastName>
            <ForeName>Chiseko</ForeName>
            <Initials>C</Initials>
            <Identifier Source="ORCID">0000-0003-2264-1696</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Date</LastName>
            <ForeName>Hidetoshi</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kanagawa</LastName>
            <ForeName>Motoi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cell Biology and Molecular Medicine, Ehime University Graduate School of Medicine, Ehime, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mitsui</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ishiura</LastName>
            <ForeName>Hiroyuki</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yoshimura</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinal-Fernandez</LastName>
            <ForeName>Iago</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Health Sciences and Faculty of Computer Science, Multimedia, and Telecommunications, Open University of Catalonia, Barcelona, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mammen</LastName>
            <ForeName>Andrew L</ForeName>
            <Initials>AL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lloyd</LastName>
            <ForeName>Thomas E</ForeName>
            <Initials>TE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Solomon H. Synder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tsuji</LastName>
            <ForeName>Shoji</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Medical Genomics, International University of Health and Welfare, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shimizu</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Physical Therapy, Tokyo University of Technology, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toda</LastName>
            <ForeName>Tatsushi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Division of Molecular Brain Science, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goto</LastName>
            <ForeName>Jun</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, International University of Health and Welfare, Ichikawa Hospital, Chiba, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AR076390</GrantID>
            <Acronym>AR</Acronym>
            <Agency>NIAMS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ann Neurol</MedlineTA>
        <NlmUniqueID>7707449</NlmUniqueID>
        <ISSNLinking>0364-5134</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018979" MajorTopicYN="N">Myositis, Inclusion Body</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059467" MajorTopicYN="Y">Transcriptome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>Potential Conflicts of Interest. Nothing to report.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>12</Hour>
          <Minute>6</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35064929</ArticleId>
        <ArticleId IdType="mid">NIHMS1797980</ArticleId>
        <ArticleId IdType="pmc">PMC9092834</ArticleId>
        <ArticleId IdType="doi">10.1002/ana.26304</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lloyd TE, Mammen AL, Amato AA, et al.
Evaluation and construction of diagnostic criteria for inclusion body myositis. Neurology
2014;83:426–433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4132572</ArticleId>
            <ArticleId IdType="pubmed">24975859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weihl CC, Mammen AL. Sporadic inclusion body myositis—a myodegenerative disease or an inflammatory myopathy. Neuropathol Appl Neurobiol
2017;43:82–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28111778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weihl CC. Sporadic inclusion body myositis and other rimmed vacuolar myopathies. Continuum (Minneap Minn)
2019;25:1586–1598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31794461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Britson KA, Yang SY, Lloyd TE. New developments in the genetics of inclusion body myositis. Curr Rheumatol Rep
2018;20:26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6374100</ArticleId>
            <ArticleId IdType="pubmed">29611059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keller CW, Schmidt J, Lünemann JD. Immune and myodegenerative pathomechanisms in inclusion body myositis. Ann Clin Transl Neurol
2017;4:422–445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5454400</ArticleId>
            <ArticleId IdType="pubmed">28589170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenberg SA, Sanoudou D, Haslett JN, et al.
Molecular profiles of inflammatory myopathies. Neurology
2002;59:1170–1182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12391344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cortese A, Plagnol V, Brady S, et al.
Widespread RNA metabolism impairment in sporadic inclusion body myositis TDP43-proteinopathy. Neurobiol Aging
2014;35:1491–1498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3988933</ArticleId>
            <ArticleId IdType="pubmed">24462217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amici DR, Pinal-Fernandez I, Mázala DA, et al.
Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis. Acta Neuropathol Commun
2017;5:24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5363023</ArticleId>
            <ArticleId IdType="pubmed">28330496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamann PD, Roux BT, Heward JA, et al.
Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis. Sci Rep
2017;7:8024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5556005</ArticleId>
            <ArticleId IdType="pubmed">28808260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al.
Identification of distinctive interferon gene signatures in different types of myositis. Neurology
2019;93:e1193–e1204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6808530</ArticleId>
            <ArticleId IdType="pubmed">31434690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, et al.
Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis
2020;79:1234–1242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32546599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ivanidze J, Hoffmann R, Lochmüller H, et al.
Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-γ signaling cascade in attacked versus nonattacked myofibers. Am J Pathol
2011;179:1347–1359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3157228</ArticleId>
            <ArticleId IdType="pubmed">21855683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parker KC, Kong SW, Walsh RJ, et al.
Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis. Muscle Nerve
2009;39:739–753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2753483</ArticleId>
            <ArticleId IdType="pubmed">19291799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikenaga C, Kubota A, Kadoya M, et al.
Clinicopathologic features of myositis patients with CD8-MHC-1 complex pathology. Neurology
2017;89:1060–1068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28794251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoogendijk JE, Amato AA, Lecky BR, et al.
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis. Neuromuscul Disord
2004;14:337–345.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15099594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rose MR, ENMC IBM Working Group. 188th ENMC international workshop: inclusion body myositis. Neuromuscul Disord
2013;23:1044–1055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24268584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allenbach Y, Mammen AL, Benveniste O, et al.
224th ENMC international workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Neuromuscul Disord
2018;28:87–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29221629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bucelli RC, Pestronk A. Immune myopathies with perimysial pathology: clinical and laboratory features. Neurol Neuroimmunol Neuroinflamm
2018;5:e434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5773856</ArticleId>
            <ArticleId IdType="pubmed">29359173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?
Chest
2010;138:1464–1474.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21138882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med
2016;23:218–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5006392</ArticleId>
            <ArticleId IdType="pubmed">27594777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao Y, Smyth GK, Shi W. The subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res
2013; 41:e108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3664803</ArticleId>
            <ArticleId IdType="pubmed">23558742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics
2010;26:139–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2796818</ArticleId>
            <ArticleId IdType="pubmed">19910308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ritchie ME, Phipson B, Wu D, et al.
Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res
2015;43:e47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4402510</ArticleId>
            <ArticleId IdType="pubmed">25605792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gang Q, Bettencourt C, Machado PM, et al.
Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiol Aging
2016;47:218.e1–218.e9.</Citation>
        </Reference>
        <Reference>
          <Citation>Gang Q, Bettencourt C, Machado PM, et al.
The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiol Aging
2015;36:1766.e1–1766.e3.</Citation>
        </Reference>
        <Reference>
          <Citation>Güttsches AK, Brady S, Krause K, et al.
Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol
2017;81:227–239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5323275</ArticleId>
            <ArticleId IdType="pubmed">28009083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johari M, Arumilli M, Palmio J, et al.
Association study reveals novel risk loci for sporadic inclusion body myositis. Eur J Neurol
2017;24:572–577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28233382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindgren U, Roos S, Hedberg Oldfors C, et al.
Mitochondrial pathology in inclusion body myositis. Neuromuscul Disord
2015;25:281–288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25638290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mastaglia FL, Rojana-udomsart A, James I, et al.
Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms. Neuromuscul Disord
2013;23:969–974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24103330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rothwell S, Cooper RG, Lundberg IE, et al.
Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. Arthritis Rheumatol
2017;69:1090–1099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5516174</ArticleId>
            <ArticleId IdType="pubmed">28086002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scott AP, Laing NG, Mastaglia F, et al.
Investigation of NOTCH4 coding region polymorphisms in sporadic inclusion body myositis. J Neuroimmunol
2012;250:66–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22732452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weihl CC, Baloh RH, Lee Y, et al.
Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord
2015;25:289–296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4372452</ArticleId>
            <ArticleId IdType="pubmed">25617006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Panaite PA, Stalder AK, Ipsen S, et al.
mTOR is expressed in polymyositis but not in sporadic inclusion body myositis. Clin Neuropathol
2015;34:371–373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26104108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenberg SA, Pinkus JL, Kong SW, et al.
Highly differentiated cytotoxic T cells in inclusion body myositis. Brain
2019;142:2590–2604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31326977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morosetti R, Broccolini A, Sancricca C, et al.
Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol Aging
2010;31:1205–1214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18823681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinkus JL, Amato AA, Taylor JP, Greenberg SA. Abnormal distribution of heterogeneous nuclear ribonucleoproteins in sporadic inclusion body myositis. Neuromuscul Disord
2014;24:611–616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24857366</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ulgen E, Ozisik O, Sezerman OU. pathfindR: an R package for comprehensive identification of enriched pathways in omics data through active subnetworks. Front Genet
2019;10:858.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6773876</ArticleId>
            <ArticleId IdType="pubmed">31608109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marie H, Pratt SJ, Betson M, et al.
The LIM protein Ajuba is recruited to cadherin-dependent cell junctions through an association with alpha-catenin. J Biol Chem
2003;278:1220–1228.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12417594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon O, Jeong SJ, Kim SO, et al.
Modulation of E-cadherin expression by K-Ras; involvement of DNA methyltransferase-3b. Carcinogenesis
2010;31:1194–1201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20375073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van den Bossche J, Malissen B, Mantovani A, et al.
Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood
2012;119:1623–1633.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22174153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano S, Nose A, Hatta K, et al.
Calcium-dependent cell-cell adhesion molecules (cadherins): subclass specificities and possible involvement of actin bundles. J Cell Biol
1987;105:2501–2510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2114731</ArticleId>
            <ArticleId IdType="pubmed">3320048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagafuchi A, Shirayoshi Y, Okazaki K, et al.
Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature
1987;329:341–343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3498123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lock JG, Stow JL. Rab11 in recycling endosomes regulates the sorting and basolateral transport of E-cadherin. Mol Biol Cell
2005;16:1744–1755.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1073657</ArticleId>
            <ArticleId IdType="pubmed">15689490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogler TO, Wheeler JR, Nguyen ED, et al.
TDP-43 and RNA form amyloid-like myo-granules in regenerating muscle. Nature
2018;563:508–513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6324568</ArticleId>
            <ArticleId IdType="pubmed">30464263</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
